Am I a Candidate for Lu-177 PSMA Therapy? A Plain-Language Guide to Eligibility for Men with Metastatic Castration-Resistant Prostate Cancer

Why Eligibility Matters Before You Start

If you have metastatic castration-resistant prostate cancer (mCRPC) and your current treatment has stopped working, you may have heard about Lu-177 PSMA therapy. It is a targeted radiation treatment that may help slow or shrink prostate cancer that has spread. But not every man with mCRPC will qualify.

Eligibility involves several checkpoints — your scan results, your treatment history, and how well your organs are working. This guide explains each one in plain language so you know what to ask at your next oncology appointment.

If you want a broader overview of how this therapy works before reading about eligibility, see our guide: What Is Lu-177 Therapy? A Patient-Friendly Guide to How It Works, What to Expect, and Whether It Might Be Right for You.

What Is Lu-177 PSMA Therapy?

Lu-177 PSMA therapy is a radioligand therapy. It uses a molecule that seeks out a protein called PSMA (prostate-specific membrane antigen) on the surface of prostate cancer cells. Once it finds those cells, it delivers a small dose of radiation directly to them.

According to the Prostate Cancer Foundation, PSMA appears on nearly all prostate cancer cells but not on most normal tissue. The Lu-177 molecule binds to PSMA-expressing cancer cells and delivers targeted radiation while limiting damage to nearby healthy tissue.

Because of how it works, the therapy only makes sense if your tumor cells carry enough PSMA protein. That is the first and most important eligibility checkpoint.

The 5 Key Eligibility Checkpoints

1. You Must Have a Positive PSMA PET Scan

First, you need a PSMA PET scan. This scan uses a small amount of radioactive tracer to highlight cancer cells that carry the PSMA protein. If enough of your cancer cells show up on this scan, you may be eligible for Lu-177 PSMA therapy.

The VISION trial — the large study that led to the first FDA approval of this therapy — required that a metastatic lesion show PSMA uptake greater than that of the liver on a 68Ga-PSMA-11 PET scan. Think of the liver as a reference point. Your cancer spots need to appear "brighter" on the scan than your liver for this standard to be met.

There is also a flip side. If cancer lesions appear on a standard CT scan but do not show up on the PSMA PET scan, those lesions are considered PSMA-negative. PSMA-negative areas would not respond to Lu-177 PSMA therapy, which means the treatment would miss part of your cancer — and that can make you ineligible.

The Prostate Cancer Foundation notes that a positive PSMA PET scan is a required step before a patient can be selected for Lu-177 PSMA treatment.

Several approved tracers can be used for this scan. ASCO guidelines recommend using either 68Ga-PSMA-11, piflufolastat F-18, or flotufolastat F-18 to determine treatment eligibility. Your doctor will choose the one available at your center.

2. You Must Have mCRPC With Documented Disease Progression

Lu-177 PSMA therapy is approved for men whose prostate cancer has become "castration resistant." This means the cancer kept growing even while testosterone levels were very low — whether from hormone therapy (injections or pills) or surgical removal of the testicles.

You also need metastatic disease, meaning the cancer has spread beyond the prostate to bones, lymph nodes, or organs. Your doctor will confirm this through bone scans, CT scans, or MRI.

Progression must also be documented. This typically means your PSA level has risen on at least two separate measurements, or new lesions have appeared on imaging.

3. You Must Have Received Prior Standard Treatments

Lu-177 PSMA therapy is not a first-line treatment. The FDA has approved it for men who have already received earlier lines of therapy, and the approved setting recently expanded.

The original approval (March 2022): The FDA first approved Lu-177 PSMA-617 for adult patients with PSMA-positive mCRPC who had already been treated with both an androgen receptor pathway inhibitor (ARPI, such as abiraterone or enzalutamide) and taxane-based chemotherapy (such as docetaxel).

The expanded approval (March 2025): The FDA expanded eligibility to include patients with PSMA-positive mCRPC who have received an ARPI and are considered appropriate candidates to delay taxane-based chemotherapy. This means the therapy may now be an option before chemotherapy for some patients.

In plain terms:

• If you have already had hormone therapy (ARPI) and chemotherapy (taxane): you may qualify under the original approval.
• If you have had hormone therapy (ARPI) but not yet chemotherapy, and your doctor thinks it is appropriate to delay chemo: you may qualify under the expanded approval.

This expanded approval was based on the PSMAfore Phase 3 trial, which showed that Lu-177 PSMA-617 significantly reduced disease progression compared with switching to a different ARPI in taxane-naïve patients. You can read more about those results here: PSMAfore: Lu-177 PSMA Therapy Before Chemotherapy Shows Benefit.

4. Your Organs Must Be Functioning Well Enough

Lu-177 PSMA therapy is processed through your kidneys and can affect your bone marrow, the tissue that makes blood cells. Your doctor will run blood tests before treatment to confirm your body can handle it safely.

Specific thresholds may vary by center, but here is a general picture based on published clinical data:

• Bone marrow / blood counts: You need adequate levels of white blood cells, platelets, and hemoglobin. The VISION trial required white blood cell count ≥2.5 × 10⁹/L, platelets ≥100 × 10⁹/L, and hemoglobin ≥9 g/dL. Low blood counts from prior chemotherapy can be a concern.
• Kidney function: Your kidneys must be working adequately. A consensus statement from the Society of Nuclear Medicine and Molecular Imaging identified a minimum baseline kidney filtration rate (GFR) of 30 mL/min as a practical threshold, with closer monitoring recommended below that level.
• Liver function: Blood tests for bilirubin and liver enzymes (ALT, AST) must be within acceptable ranges.

If your organ function falls short, your care team may look at whether the situation can be improved, or whether treatment in a closely monitored setting is still reasonable.

5. Your Overall Physical Condition (Performance Status)

Doctors use a scoring system called the ECOG performance status scale to measure how well you can carry out daily activities. It runs from 0 (fully active) to 4 (completely disabled).

Most clinical trials and treatment programs for Lu-177 PSMA therapy require an ECOG score of 0, 1, or 2, meaning you can care for yourself and spend at least half your waking hours up and about, even if heavy physical work is not possible. A score of 3 or 4 generally makes treatment less safe or less likely to help.

This is not a rigid rule at every center, but it is a standard checkpoint your oncologist will discuss with you.

Who Is Typically NOT Eligible?

Some situations may make Lu-177 PSMA therapy unsuitable. These include:

• A negative PSMA PET scan — meaning your cancer does not carry enough PSMA protein
• PSMA-negative lesions visible on CT that do not appear on the PSMA PET scan, suggesting parts of your cancer would not respond
• Severely reduced kidney function below the minimum threshold
• Very low blood cell counts that cannot be safely managed
• Very poor performance status (ECOG 3 or 4)
• Uncontrolled or untreated brain metastases
• Severe liver dysfunction
• No prior ARPI therapy

If you do not meet the current eligibility criteria, your oncologist may recommend a clinical trial or suggest revisiting eligibility if your condition changes. Research into who benefits most from this therapy is ongoing.

How the Eligibility Picture Has Changed Over Time

When Lu-177 PSMA therapy first received FDA approval in 2022, it was reserved for men who had already gone through both hormone therapy and chemotherapy. The VISION trial enrolled patients who had received at least one novel hormone therapy agent and one to two taxane chemotherapy regimens.

The March 2025 FDA label expansion changed this. Lu-177 PSMA therapy is now an option earlier in the disease course, before chemotherapy, for the right patients. This reflects results from the PSMAfore trial, which showed meaningful benefit in taxane-naïve patients who had progressed on one ARPI.

Researchers are also studying Lu-177 PSMA therapy in earlier disease settings and in combination with other treatments. The eligibility landscape will likely keep shifting as more evidence comes in.

For a step-by-step look at what happens during a Lu-177 PSMA infusion visit, see: What Happens During a Lu-177 PSMA Infusion? A Step-by-Step Guide for First-Time Patients.

Questions to Bring to Your Oncologist

Coming to your appointment prepared helps you make the most of your time. Here are some questions worth asking:

• Have I had a PSMA PET scan? If not, should I?
• Did my PSMA PET scan meet the eligibility criteria used in the VISION or PSMAfore trials?
• Have I received the treatments typically required before Lu-177 PSMA therapy?
• Are my blood counts and kidney function within an acceptable range?
• Given my current health, am I likely to benefit more than I would be harmed?
• Are there any clinical trials of Lu-177 PSMA therapy I might qualify for?
• If I do not qualify now, what would need to change for me to qualify later?

A Note on Access and India

For patients in India or those considering traveling for treatment, Lu-177 PSMA therapy is available at a growing number of specialized nuclear medicine centers. Eligibility criteria are largely the same internationally — PSMA PET scan result, treatment history, organ function, and performance status. Access to PSMA PET imaging has also expanded considerably in recent years. Our article on why India is becoming a global destination for Lutetium therapy covers what to expect logistically.

After treatment, many patients have practical questions about daily life. Our article Can I hug my grandchildren after a Lutetium infusion? covers radiation safety at home in plain language.

When to Talk to Your Doctor

If you have mCRPC and your current treatment has stopped working, now is the time to ask your oncologist about PSMA PET imaging and whether Lu-177 PSMA therapy may be an option. Do not wait for your doctor to bring it up — come prepared with the questions above. Earlier conversations tend to leave more choices open.

---

This article is for general information and is not a substitute for medical advice. Always consult your oncologist or care team about your specific situation.